News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
810,940 Results
Type
Article (79539)
Company Profile (542)
Press Release (730857)
Multimedia
Podcasts (136)
Webinars (16)
Section
Business (223885)
Career Advice (3663)
Deals (38292)
Drug Delivery (129)
Drug Development (88965)
Employer Resources (185)
FDA (17729)
Job Trends (16751)
News (381264)
Policy (37593)
Tag
Academia (2995)
Academic (2)
Accelerated approval (7)
Adcomms (32)
Allergies (100)
Alliances (55729)
ALS (112)
Alzheimer's disease (1534)
Antibody-drug conjugate (ADC) (184)
Approvals (17677)
Artificial intelligence (342)
Autoimmune disease (34)
Automation (18)
Bankruptcy (381)
Best Places to Work (12578)
BIOSECURE Act (22)
Biosimilars (124)
Biotechnology (375)
Bladder cancer (95)
Brain cancer (37)
Breast cancer (374)
Cancer (2876)
Cardiovascular disease (232)
Career advice (3115)
Career pathing (34)
CAR-T (199)
CDC (33)
Cell therapy (541)
Cervical cancer (23)
Clinical research (72182)
Collaboration (1028)
Company closure (3)
Compensation (641)
Complete response letters (30)
COVID-19 (2891)
CRISPR (64)
C-suite (313)
Cystic fibrosis (116)
Data (2846)
Decentralized trials (2)
Denatured (47)
Depression (64)
Diabetes (323)
Diagnostics (6923)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (150)
Drug pricing (146)
Drug shortages (35)
Duchenne muscular dystrophy (121)
Earnings (92485)
Editorial (48)
Employer branding (25)
Employer resources (163)
Events (126720)
Executive appointments (875)
FDA (19304)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (923)
Gene editing (141)
Generative AI (31)
Gene therapy (409)
GLP-1 (883)
Government (5201)
Grass and pollen (6)
Guidances (179)
Healthcare (20841)
Huntington's disease (28)
IgA nephropathy (39)
Immunology and inflammation (168)
Immuno-oncology (7)
Indications (36)
Infectious disease (3066)
Inflammatory bowel disease (162)
Inflation Reduction Act (12)
Influenza (64)
Intellectual property (114)
Interviews (706)
IPO (17501)
IRA (53)
Job creations (4637)
Job search strategy (2543)
Kidney cancer (14)
Labor market (45)
Layoffs (573)
Leadership (25)
Legal (9437)
Liver cancer (83)
Lung cancer (408)
Lymphoma (197)
Machine learning (9)
Management (65)
Manufacturing (399)
MASH (91)
Medical device (14548)
Medtech (14553)
Mergers & acquisitions (21468)
Metabolic disorders (867)
Multiple sclerosis (100)
NASH (23)
Neurodegenerative disease (134)
Neuropsychiatric disorders (37)
Neuroscience (2231)
NextGen: Class of 2025 (7566)
Non-profit (5077)
Now hiring (46)
Obesity (459)
Opinion (283)
Ovarian cancer (96)
Pain (115)
Pancreatic cancer (108)
Parkinson's disease (184)
Partnered (24)
Patents (292)
Patient recruitment (140)
Peanut (53)
People (63404)
Pharmaceutical (115)
Pharmacy benefit managers (24)
Phase I (22398)
Phase II (31480)
Phase III (23662)
Pipeline (1597)
Policy (213)
Postmarket research (3255)
Preclinical (10107)
Press Release (72)
Prostate cancer (138)
Psychedelics (39)
Radiopharmaceuticals (276)
Rare diseases (489)
Real estate (7004)
Recruiting (75)
Regulatory (25495)
Reports (45)
Research institute (2651)
Resumes & cover letters (584)
Rett syndrome (9)
RNA editing (9)
RSV (54)
Schizophrenia (91)
Series A (158)
Series B (105)
Service/supplier (22)
Sickle cell disease (64)
Special edition (22)
Spinal muscular atrophy (166)
Sponsored (36)
Startups (4158)
State (2)
Stomach cancer (16)
Supply chain (79)
Tariffs (63)
The Weekly (87)
Vaccines (871)
Venture capitalists (51)
Weight loss (313)
Women's health (46)
Worklife (20)
Date
Today (32)
Last 7 days (518)
Last 30 days (2492)
Last 365 days (34086)
2025 (16055)
2024 (37732)
2023 (42479)
2022 (53844)
2021 (58609)
2020 (57537)
2019 (51145)
2018 (38988)
2017 (36469)
2016 (37142)
2015 (43155)
2014 (37443)
2013 (33788)
2012 (35564)
2011 (35530)
2010 (35023)
Location
Africa (1181)
Alabama (66)
Alaska (7)
Arizona (260)
Arkansas (14)
Asia (48043)
Australia (8287)
California (7408)
Canada (2289)
China (674)
Colorado (316)
Connecticut (330)
Delaware (188)
Europe (108911)
Florida (1095)
Georgia (247)
Idaho (63)
Illinois (681)
India (30)
Indiana (366)
Iowa (15)
Japan (217)
Kansas (113)
Kentucky (29)
Louisiana (15)
Maine (73)
Maryland (1053)
Massachusetts (5621)
Michigan (263)
Minnesota (454)
Mississippi (3)
Missouri (92)
Montana (32)
Nebraska (26)
Nevada (79)
New Hampshire (72)
New Jersey (2059)
New Mexico (31)
New York (2068)
North Carolina (1187)
North Dakota (10)
Northern California (3204)
Ohio (241)
Oklahoma (16)
Oregon (43)
Pennsylvania (1581)
Puerto Rico (17)
Rhode Island (38)
South America (1554)
South Carolina (34)
South Dakota (1)
Southern California (2734)
Tennessee (121)
Texas (1096)
United States (27809)
Utah (218)
Virginia (191)
Washington D.C. (78)
Washington State (645)
West Virginia (4)
Wisconsin (79)
810,940 Results for "johnson and johnson pharmaceutical research and development llc ca".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
June 2, 2025
·
9 min read
Press Releases
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
June 3, 2025
·
19 min read
Press Releases
New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
June 13, 2025
·
9 min read
Press Releases
Johnson & Johnson’s AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
June 3, 2025
·
11 min read
Press Releases
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
April 21, 2025
·
10 min read
Press Releases
Early results from Johnson & Johnson’s trispecific antibody show promising response in heavily pretreated multiple myeloma patients
June 4, 2025
·
7 min read
Press Releases
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
April 28, 2025
·
9 min read
Press Releases
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
April 28, 2025
·
11 min read
Press Releases
Johnson & Johnson Launches KINCISE™ 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures
June 3, 2025
·
7 min read
Press Releases
Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ in the US, Redefining Image Clarity in 2D Intracardiac Imaging
May 21, 2025
·
9 min read
1 of 81,094
Next
